Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer

World J Oncol. 2022 Oct;13(5):320-324. doi: 10.14740/wjon1494. Epub 2022 Oct 22.

Yi Xiang¹, Xiao Juan Lu², Yi Hang Sun³, Xia Liu¹, Yan Yang Wu⁴, Hui Rao⁴, Qiu Yang Que⁴, Qi Xiao⁵, Rui Zhu¹, Xiao Fei Feng¹, Wei Ling Lai¹, Xiao Huan Zou⁶, Ying Wang⁴, Song Qiu⁴, Li Huang^{1

7}, Hua Qiu Shi^{1

7}, Xiang Cai Wang^{1

7}

¹ Department of Oncology, The First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
² Department of Oncology, The People's Hospital of Leshan, Leshan, China.
³ School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
⁴ First Clinical Medical College, Gannan Medical University, Ganzhou, China.
⁵ Jiangkou Town Central Health Center, Ganzhou, China.
⁶ Department of Critical Care Medicine, The First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
⁷ These authors contributed equally to this work.

No abstract available